OkaiDx™ Pancreatic Cancer Detection Blood Test

Booth No: M709

Characteristic

OkaiDx™ Pancreatic Cancer Blood Test is based on non-invasive cfDNA methylation analysis. With a simple blood draw, it detects pancreatic cancer-related molecular signals and provides molecular-level adjunct testing information. Clinical validation data show that the test achieves >93.8% sensitivity for early-stage pancreatic cancer (Stage I/II) and >98.0% specificity, helping clinicians detect pancreatic cancer-related molecular signals earlier and increase confidence in early molecular adjunct detection and clinical interpretation. Compared with the conventional CA19-9 tumor marker, which may be affected by biliary obstruction, hepatitis, cholangitis, or Lewis-negative blood type, OkaiDx™ analyzes cancer-related DNA methylation signals to provide more specific molecular adjunct testing information.
This test is suitable for adoption by healthcare institutions, health screening centers, and channel partners. It can be applied to early molecular adjunct detection of pancreatic cancer, follow-up of high-risk populations, postoperative minimal residual disease (MRD) monitoring, and long-term recurrence risk management. The test is performed in a U.S. CLIA/CAP dual-certified clinical laboratory. The related technology has been granted a U.S. patent and continues to pursue international patent protection through the PCT route. EG BioMed can also help partners establish differentiated molecular testing services aligned with international quality standards.